Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
Upstream Bio presented new responder analyses from the Phase 2 VIBRANT trial of verekitug in CRSwNP, showing that 79% of treated participants achieved clinically meaningful improvements in nasal polyp score. The drug also drove high responder rates across secondary endpoints: 83% in total symptom score, 78% in Lund-Mackay CT score, 72% in nasal congestion, and 69% in sense of smell, all significantly outperforming placebo.
Key figures
- Drug Name
- verekitug
- Phase Of Trial
- Phase 2
- Nps responder rate
- 79%
- Trial participants
- 81
- Smell responder rate
- 69%
- Phase 3 initiation target
- Q1 2027
- Lund mackay responder rate
- 78%
- Total symptom responder rate
- 83%
- Nps placebo adjusted reduction
- -1.95
- Nasal congestion responder rate
- 72%
- Surgery corticosteroid reduction
- 76%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.